Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A N Lieberman

Showing results (31-40 of 70) with videos related to

Pageof 7
Sort By:
New York State Journal of Medicine|July 1, 1980
Parkinson's disease; acute urinary retentionA N Lieberman, A Lebowitz, M Leibowitz, et al.
Military Medicine|March 1, 1970
Metrazol and the evaluation of seizuresA N Lieberman, V S Caviness, C L Shattuck
The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques|August 1, 1987
D-1 and D-2 agonists in Parkinson's diseaseA N Lieberman, M Goldstein, G Gopinathan, et al.
Lancet (London, England)|September 4, 1976
Lergotrile in Parkinson's diseaseA N Lieberman, M Kupersmith, E Estey, et al.
Advances in Neurology|January 1, 1990
Mesulergine: a dopamine agonist with novel properties in Parkinson's diseaseA N Lieberman, G Gopinathan, P Pasternack, et al.
New York State Journal of Medicine|December 1, 1987
Deprenyl versus placebo in Parkinson disease: a double-blind studyA N Lieberman, G Gopinathan, A Neophytides, et al.
Advances in Neurology|January 1, 1983
The effects of pergolide on the cardiovascular system of 40 patients with Parkinson's diseaseM Leibowitz, A N Lieberman, A Neophytides, et al.
The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques|February 1, 1984
Should dopamine agonists be given early or late? A review of nine years experience with bromocriptineA N Lieberman, G Gopinathan, H Hassouri, et al.
Advances in Neurology|January 1, 1984
Pergolide and lisuride in advanced Parkinson's diseaseA N Lieberman, G Gopinathan, A Neophytides, et al.
Advances in Neurology|January 1, 1990
The antiparkinsonian activity of dopamine agonists and their interaction with central dopamine receptor subtypesM Goldstein, A N Lieberman, N Takasugi, et al.
Pageof 7

Showing results (31-40 of 70) with videos related to

Sort By:
Pageof 7
New York State Journal of Medicine|July 1, 1980
Parkinson's disease; acute urinary retentionA N Lieberman, A Lebowitz, M Leibowitz, et al.
Military Medicine|March 1, 1970
Metrazol and the evaluation of seizuresA N Lieberman, V S Caviness, C L Shattuck
The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques|August 1, 1987
D-1 and D-2 agonists in Parkinson's diseaseA N Lieberman, M Goldstein, G Gopinathan, et al.
Lancet (London, England)|September 4, 1976
Lergotrile in Parkinson's diseaseA N Lieberman, M Kupersmith, E Estey, et al.
Advances in Neurology|January 1, 1990
Mesulergine: a dopamine agonist with novel properties in Parkinson's diseaseA N Lieberman, G Gopinathan, P Pasternack, et al.
New York State Journal of Medicine|December 1, 1987
Deprenyl versus placebo in Parkinson disease: a double-blind studyA N Lieberman, G Gopinathan, A Neophytides, et al.
Advances in Neurology|January 1, 1983
The effects of pergolide on the cardiovascular system of 40 patients with Parkinson's diseaseM Leibowitz, A N Lieberman, A Neophytides, et al.
The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques|February 1, 1984
Should dopamine agonists be given early or late? A review of nine years experience with bromocriptineA N Lieberman, G Gopinathan, H Hassouri, et al.
Advances in Neurology|January 1, 1984
Pergolide and lisuride in advanced Parkinson's diseaseA N Lieberman, G Gopinathan, A Neophytides, et al.
Advances in Neurology|January 1, 1990
The antiparkinsonian activity of dopamine agonists and their interaction with central dopamine receptor subtypesM Goldstein, A N Lieberman, N Takasugi, et al.
Pageof 7